Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial

MT Newswires Live03-26

Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.

Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.

The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.

The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.

The company's shares were up more than 18% in recent Wednesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522810870?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-26 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522810870","market":"sg","top_or_hot":-1,"title":"Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.</p><p>Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.</p><p>The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.</p><p>The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.</p><p>The company's shares were up more than 18% in recent Wednesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-26 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Leap <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.</p><p>Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.</p><p>The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.</p><p>The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.</p><p>The company's shares were up more than 18% in recent Wednesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522810870","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522810870","pubTimestamp":1742992311,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Leap Therapeutics  said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.The company's shares were up more ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Leap Therapeutics表示新数据显示Sirexatamab可提高结直肠癌试验的生存率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"LPTX":0.9},"content_text":"Leap Therapeutics (LPTX) said Wednesday that updated findings from its phase 2 trial indicate that sirexatamab combined with bevacizumab and chemotherapy improves progression-free survival and overall response rate in patients with advanced colorectal cancer.Leap reported that patients with elevated DKK1 protein levels who were treated with sirexatamab in addition to bevacizumab and chemotherapy had a 32% higher overall response rate and lived 3.5 months longer without their cancer worsening compared with patients receiving only bevacizumab and chemotherapy.The company also said that patients who had not previously received anti-VEGF therapy saw a 22% higher ORR and lived 2.6 months longer without disease progression, though overall survival data is still being collected.The company said the new data supports plans to move sirexatamab into a phase 3 trial, focusing on colorectal cancer patients with elevated DKK1 protein levels or no prior anti-VEGF therapy.The company's shares were up more than 18% in recent Wednesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522810870"}